轉知訊息
轉知—吉立亞醫藥公司 (Gilead Sciences) 研究招募案 RESONATE
日期：2024/07/10轉知—吉立亞醫藥公司 (Gilead Sciences) 研究招募案RESONATE，以下面研究方向為主
- Real world data on B/F/TAF (switch to B/F/TAF, immediate start/restart on B/F/TAF)
- Data on the burden of HIV and novel implementation strategies to improve access, sustain engagement, and optimize ART in communities disproportionately impacted by HIV.
- Drivers and barriers for implementation of LEN for heavily treatment experienced people with HIV
- Effectiveness, safety, and adherence/persistence of LEN for heavily treatment experienced people with HIV in real world settings
研究招募期間：2024 July 8th ~ 2024 Nov. 18th (23:59 PST)
研究獎金：總共7,000,000 USD (預期招募十五個研究案)
研究摘要建議不超過兩頁，採線上投稿方式進行 Gilead Optics online portal
完整的招募案內容及研究方向可參考網址：RESONATE 2024 RFP Program
備註1：此次招募案的審稿件方式為先送先審(evaluate on a rolling basis)，直到所提供之研究獎金耗盡即結束招募，因此鼓勵有意願的醫護人員把握時間提早投稿。
備註2:：此次招募案涵蓋Lenacapavir for HTE PWH的研究範圍，僅適用於Lenacapavir已上市之國家。
若申請者有任何疑問或需要更多資訊，請寫信至 RESONATE@gilead.com
或聯繫
Norah Lai 賴思薰
Associate Director, M.D.
HIV Medical Affairs, Gilead Science Taiwan
Office: +886 2 8729 6737
Mobile:+ 886 932 816 489
E-mail: Norah.Lai@gilead.com
